Table 3 World Health Organization (WHO) policy guidelines on collaborative tuberculosis (TB)/HIV activities and the management of HIV infection, TB and multidrug-resistant TB (MDR-TB)
From: Management of HIV-associated tuberculosis in resource-limited settings: a state-of-the-art review
Guidelines/year | Details | Reference |
|---|---|---|
Guidelines for collaborative TB/HIV activities (2012) | World Health Organization. WHO policy on collaborative TB/HIV activities. Guidelines for national programmes and stakeholders. 2012. World Health Organization, Geneva. WHO/HTM/TB/2012.1. http://whqlibdoc.who.int/publications/2012/9789241503006_eng.pdf | [10] |
Antiretroviral treatment guidelines (2013) | World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach, June 2013. WHO, Geneva. Accessible at: http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf. | [11] |
Tuberculosis treatment guidelines (2010) | World Health Organization. Treatment of tuberculosis: guidelines - fourth edition. World Health Organization, Geneva, 2010. WHO/HTM/TB/2009.420 Accessible at: http://whqlibdoc.who.int/publications/2010/9789241547833_eng.pdf | [12] |
Drug-resistant TB treatment guidelines (2011) | World Health Organization. Guidelines for the management of drug-resistant tuberculosis: 2011 update. WHO, Geneva. WHO/HTM/TB/2011.6. Accessible at: http://whqlibdoc.who.int/publications/2011/9789241501583_eng.pdf. | [13] |